Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 123 for:    hypertension "vitamin d"

Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03821922
Recruitment Status : Not yet recruiting
First Posted : January 30, 2019
Last Update Posted : January 30, 2019
Sponsor:
Information provided by (Responsible Party):
Dongyu Wang, First Affiliated Hospital, Sun Yat-Sen University

Brief Summary:

Hypertensive disorder complicating pregnancy is a set of diseases of pregnancy coexisting with elevated blood pressure. The incidence of it is approximately 5-12%. Pregnancy-induced hypertension is a pregnancy-specific disorder, severely impairing both maternal and fetal health, and the major cause of maternal and perinatal mortality rate increased. But so far, the specific etiology is still unclear.

Recently, fibroblast growth factor 23 (FGF23) has emerged as key endocrine regulators of the metabolism of vitamin D and calcium and phosphorus by combining FGFR-α- Klotho receptor complex. Current studies showed that α- Klotho involved the development of gestational hypertension via the production of endothelial nitric oxide, angiogenesis, and the formation of antioxidant enzymes. On the other hand, vitamin D deficiency during pregnancy has an adverse impact on maternal and fetal health, including gestational hypertension. Therefore, the relationship of the expression of FGF23 and the development of gestational hypertension has attracted the attention of relevant scholars.

The aim of this study is to detect the difference of the expression of FGF23 between the hypertensive women and normal pregnant women.


Condition or disease
Hypertension, Pregnancy-Induced

Detailed Description:

100 pregnant women with hypertensive disorder complicating pregnancy and 200 normal pregnant control women matched for maternal and gestational age were enrolled in the study. All the subjects underwent antepartum screening in the First Affiliated Hospital of Sun Yat-sen University. Blood samples were obtained after overnight fasting at the first, second and third trimester respectively. Serum FGF23 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters.

Data were analyzed by SPSS 20.0 database. The results were expressed as mean ± standard deviations or median with interquartile range. Differences between groups were assessed by Student's unpaired t test, Mann-Whitney U test, or Chi-square test as appropriate. Correlation analysis was performed using the Spearman rank correlation method. To identify independent relationships and adjust the effects of covariates, multiple linear regression analyses were performed. P values of <0.05 were considered significant.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Expression of Endocrine Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine


Group/Cohort
pregnancy-induced pregnancy
Those women (subjects) with pregnancy-induced pregnancy.
Control
Those healthy pregnant women



Primary Outcome Measures :
  1. Expression of FGF23 [ Time Frame: up to 14 weeks ]
    expression of FGF23 in different groups in mmol/l

  2. Expression of FGF23 [ Time Frame: up to 28 weeks ]
    expression of FGF23 in different groups in mmol/l

  3. Expression of FGF23 [ Time Frame: up to 40 weeks ]
    expression of FGF23 in different groups in mmol/l



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
university hospital
Criteria

Inclusion Criteria:

  • Women with singleton pregnancy;
  • Regular antenatal examination from the first trimester;
  • Give birth in the university hospital (The 1st affiliated hospital of Sun Yat-sen University)

Exclusion Criteria:

  • Younger than 18 years old;
  • Older than 40 years old;
  • Multiple pregnancy;
  • Complicated with other diseases such as hypertension, eclampsia, thyroid diseases, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821922


Contacts
Layout table for location contacts
Contact: Dongyu Wang, M.D,PhD 86-020-87755766 dongyugd@aliyun.com

Locations
Layout table for location information
China, Guangdong
Obstetrics and Gynechology Department of the 1st affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
First Affiliated Hospital, Sun Yat-Sen University
Investigators
Layout table for investigator information
Study Director: Zilian Wang, M.D,PhD O&G Department of the 1st affiliated hospital of Sun Yat-sen University

Layout table for additonal information
Responsible Party: Dongyu Wang, Principal Investigator, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT03821922     History of Changes
Other Study ID Numbers: FGF23
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: January 30, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dongyu Wang, First Affiliated Hospital, Sun Yat-Sen University:
Hypertension, Pregnancy-Induced
FGF23

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Hypertension, Pregnancy-Induced
Pregnancy Complications
Vascular Diseases
Cardiovascular Diseases
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action